Summary & Overview
HCPCS Level II M0233: Tocilizumab Intravenous Infusion, First Dose for Hospitalized Adults
HCPCS Level II code M0233 identifies the first-dose intravenous infusion of tocilizumab-aazg for hospitalized adult patients with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation. This code captures the infusion procedure and immediate post-administration monitoring for the initial dose. Nationally, the code matters because it standardizes reporting and billing for a targeted biologic therapy used in severe COVID-19 cases, affecting hospital billing workflows and payer coverage decisions.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find information on service definitions, typical sites of service, and the clinical context for use. The publication provides benchmarks and comparative guidance on how payers recognize and reimburse this hospital-based infusion service, highlights relevant policy updates impacting coverage and documentation, and outlines operational considerations for hospitals and billing teams. This summary is written for a national audience seeking clarity on coding, billing, and payer handling of first-dose tocilizumab infusions for severe COVID-19 in hospitalized adults.
Billing Code Overview
HCPCS Level II code M0233 represents an intravenous infusion of tocilizumab-aazg, first dose, for hospitalized adult patients with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The description includes the infusion procedure and post-administration monitoring for the first dose.
-
Service type: Intravenous monoclonal antibody infusion, first dose
-
Typical site of service: Hospital inpatient settings, including intensive care units and other inpatient wards providing supplemental oxygen, non-invasive or invasive ventilation, or ECMO
Clinical & Coding Specifications
Clinical Context
A 67-year-old hospitalized patient with severe COVID-19 presents with progressive hypoxemic respiratory failure. The patient is receiving systemic corticosteroids and requires supplemental oxygen via high-flow nasal cannula. The treating team determines the patient meets criteria for immunomodulatory therapy with tocilizumab. After informed consent, the pharmacy verifies weight-based dosing for M0233 (first dose), the nursing team places a peripheral or central IV line, and the infusion is prepared under aseptic technique. The infusion is administered with continuous monitoring of vital signs during the infusion and for a period afterward to observe for infusion reactions and clinical response. Laboratory monitoring (including CBC, liver enzymes, and inflammatory markers) is obtained before and after administration per institutional protocol. If the patient progresses to non-invasive ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO), documentation reflects ongoing need for supplemental oxygen and systemic corticosteroid therapy to support billing under M0233.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure | When an E/M visit meets criteria in addition to the infusion service on the same date |